FIELD: medicine; therapy.
SUBSTANCE: invention relates to the field of medicine, namely to therapy; it is intended for the treatment or relief of cancer with BRCA deficiency. A method for the treatment or relief of cancer with BRCA deficiency in a subject who needs it is presented, including administration to the subject of therapeutically effective amount of a compound of the formula (III).
EFFECT: invention provides creation of new effective therapy of cancer with BRCA deficiency, wherein cancer with BRCA deficiency is heme cancer, colon and rectal cancer, ovarian cancer, breast cancer, cervical cancer, lung cancer, liver cancer, pancreatic cancer, lymph node cancer, colon cancer, prostate cancer, brain cancer, head and neck cancer, bone cancer, Ewing’s sarcoma, skin cancer, kidney cancer, and heart cancer.
15 cl, 5 tbl, 9 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR CANCER TREATMENT | 2016 |
|
RU2752506C2 |
| METHOD OF TREATMENT BY APPLICATION OF COMBINED THERAPY | 2010 |
|
RU2543348C2 |
| MEK INHIBITORS AND THEIR THERAPEUTIC USE | 2021 |
|
RU2812929C1 |
| QUINOLINE DERIVATIVES FOR USE IN TREATMENT OR PREVENTION OF CANCER | 2019 |
|
RU2811417C2 |
| TRIHETEROCYLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR CANCER TREATMENT | 2004 |
|
RU2360913C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
| CONFORMATIONALLY RESTRICTED PI3K AND MTOR INHIBITORS | 2014 |
|
RU2669696C2 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
| BIOMARKERS AND APPLICATIONS IN TREATING VIRAL INFECTIONS, INFLAMMATIONS OR CANCER | 2019 |
|
RU2820481C2 |
| MACROCYCLIC COMPOUNDS, APPLIED AS HISTONE DEACETYLASE INHIBITORS | 2011 |
|
RU2565076C2 |
